Demand for hypopituitarism diagnostics will increase through 2036, with MRI or CT scan holding a 41.2% share of the test type segment in 2026. Clinical diagnosis leads with a 44.5% share. The market is set to reach USD 301.1 million by 2026-end and USD 570.6 million by 2036.